Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Trial of Magnesium Dependent Tinnitus

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Michael Cevette, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT01273883
First received: January 7, 2011
Last updated: April 9, 2015
Last verified: April 2015
Results First Received: January 7, 2015  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Crossover Assignment;   Masking: Double Blind (Participant, Investigator)
Condition: Tinnitus
Interventions: Dietary Supplement: Magnesium
Other: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Magnesium First, Then Placebo Magnesium 532 mg daily for 25 days followed by 2 weeks of washout followed by 25 days of placebo.
Placebo First, Then Magnesium Placebo daily for 25 days followed by 2 weeks of washout followed by magnesium 532 mg daily for 25 days.

Participant Flow for 3 periods

Period 1:   First Intervention
    Magnesium First, Then Placebo   Placebo First, Then Magnesium
STARTED   19 [1]   19 [1] 
COMPLETED   17   18 
NOT COMPLETED   2   1 
Adverse Event                2                1 
[1] Received at least 1 dose of study drug.

Period 2:   Washout Period of 2 Weeks
    Magnesium First, Then Placebo   Placebo First, Then Magnesium
STARTED   17   18 
COMPLETED   17   18 
NOT COMPLETED   0   0 

Period 3:   Second Intervention
    Magnesium First, Then Placebo   Placebo First, Then Magnesium
STARTED   17   18 
COMPLETED   15   17 
NOT COMPLETED   2   1 
Lost to Follow-up                1                1 
Lack of Efficacy                1                0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Entire Study Population Includes groups randomized to receive magnesium first and placebo first.

Baseline Measures
   Entire Study Population 
Overall Participants Analyzed 
[Units: Participants]
 38 
Age 
[Units: Years]
Mean (Standard Deviation)
 61.45  (11.58) 
Gender 
[Units: Participants]
 
Female   13 
Male   25 
Region of Enrollment 
[Units: Participants]
 
United States   38 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Tinnitus Distress Rating   [ Time Frame: Pre-treatment, Post-treatment, up to four weeks ]

2.  Secondary:   Comparison of Average Tinnitus Handicap Inventory (THI) Across All Subjects   [ Time Frame: Pre-treatment, Post-treatment, up to four weeks ]

3.  Secondary:   Comparison of Average Tinnitus Handicap Inventory (THI) Across All Men   [ Time Frame: Pre-treatment, Post-treatment, up to four weeks ]

4.  Secondary:   Comparison of Average Tinnitus Handicap Inventory (THI) Across All Women   [ Time Frame: Pre-treatment, Post-treatment, up to four weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dr. Michael J. Cevette
Organization: Mayo Clinic
phone: 480-301-7020
e-mail: mcevette@mayo.edu


Publications:

Responsible Party: Michael Cevette, Mayo Clinic
ClinicalTrials.gov Identifier: NCT01273883     History of Changes
Other Study ID Numbers: 09-008292
Study First Received: January 7, 2011
Results First Received: January 7, 2015
Last Updated: April 9, 2015